On Invalid Date, Enlivex Therapeutics (NASDAQ: ENLV) reported Q2 2024 earnings per share (EPS) of -$0.16, up 56.76% year over year. Total Enlivex Therapeutics earnings for the quarter were -$3.10 million. In the same quarter last year, Enlivex Therapeutics's earnings per share (EPS) was -$0.37.
As of Q3 2024, Enlivex Therapeutics's earnings has grown year over year. Enlivex Therapeutics's earnings in the past year totalled -$22.29 million.
What was ENLV's revenue last quarter?
On Invalid Date, Enlivex Therapeutics (NASDAQ: ENLV) reported Q2 2024 revenue of $0.00 up N/A year over year. In the same quarter last year, Enlivex Therapeutics's revenue was $0.00.
What was ENLV's revenue growth in the past year?
As of Q3 2024, Enlivex Therapeutics's revenue has grown null year over year. Enlivex Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.